This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kyriazis, A. P. Articles by Fogh, J. Search for Related Content PubMed PubMed Citation Articles by Kyriazis, A. P. Articles by Fogh, J.

Response of Nude Mouse-grown Human Urothelial Cancer to cis-Diammine-dichloroplatinum(II), Diammine[1,1-cyclobutanedicarboxylato(2-)-O,O'-platinum], and Mitoguazone Dihydrochloride^{1 ,2}

Department of Pathology, University of Medicine and Dentistry of New Jersey, New Jersey Medical School, Newark, New Jersey 07103 [A. P. K., A. A. K.]; Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [A. Y.]; and Sloan-Kettering Institute for Cancer Research, Rye, New York 10580 [J. F.]

A comparative study of the effect of cis-diamminedichloroplatinum(II) (cisplatin), diammine[1,1-cyclobutanedicarboxylato(2-)-O,O'-platinum] (carboplatin), and mitoguazone dihydrochloride on urothelial cancer was conducted using transitional cell carcinomas of the urinary bladder grown in the nude mouse. Tumors SW-780 and TCC-K1 represented transitional cell carcinoma, Grade II, whereas Tumor PR49 represented a fast-growing Grade III neoplasm. Of the agents studied, cisplatin was most effective, resulting in tumor response related to the dose administered. Response to carboplatin was clearly related to treatment schedule. For the same amount of total dose administered, better results were obtained when treatment was given three times weekly instead of once every week. Furthermore, cisplatin was more effective against the less differentiated PR49 tumor in contrast to carboplatin, which showed more activity against the better differentiated SW-780 and TCC-K1 tumors. None of the tumors tested responded to mitoguazone dihydrochloride. The results of the present study may assist in formulating better treatment modalities against urothelial cancer, taking into account factors such as tumor grade, growth rate, treatment schedule, and the patient's tolerance which may ultimately influence tumor response.

¹ Supported by Grant CA-34159 from the National Cancer Institute through the National Bladder Cancer Project.

² This work is dedicated to the memory of Dr. Jørgen Fogh, who passed away on December 28, 1984.

³ To whom requests for reprints should be addressed, at Department of Pathology, UMDNJ-New Jersey Medical School, 100 Bergen Street, Newark, NJ 07103.

Received 10/25/84. Revised 1/23/85. Accepted 2/ 4/85.